1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
62354EC3C796FAFED8525764700247FD5
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/onglyza-case-study-navigating-new-safety-concerns-to-win-market-approval-in-diabetes?OpenDocument
18
19OpenDocument
203.94.196.192
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




Products & Services Sales and Marketing New Product Development and Launch Planning and Coordinating Launch Communication Activities

Onglyza Case Study: Navigating New Safety Concerns To Win Market Approval In Diabetes

ID: 5068


Features:

Graphics


Pages/Slides: 41


Published: Pre-2014


Delivery Format: Online PDF Document


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from "Onglyza Case Study: Navigating New Safety Concerns to Win Market Approval in Diabetes"


STUDY OVERVIEW

This case study reviews the opportunities and challenges faced by Bristol-Myers Squibb and AstraZeneca at the tail end of the development of Onglyza (saxagliptin), a treatment for type 2 diabetes. A second generation DPP-4 inhibitor, Onglyza was poised to follow on the success of Merck's Januvia when development partners BMS and AZ had to deal with a changing regulatory environment relative to safety. After its pivotal clinical trials had been launched, the FDA issued new, more stringent requirements for assessing safety of diabetes therapies, in particular for cardiovascular risk. The saxagliptin development team had to respond to these requirements as it tried to gain approval in this new regulatory climate. This study also reviews FDA's new requirements for assessing the safety of diabetes therapies in clinical testing. Executives and managers can use this research to gain insights into methods for navigating new safety concerns to win market approval in diabetes.

KEY TOPICS

  • Market Entry for Second Generation DPP-4 Inhibitor
  • Initial Product Profile Promised a Clear Path to Market
  • Navigating a Changing Regulatory Environment
  • Responding to New FDA Guidance for Developing Anti-Diabetes Products

SAMPLE LESSONS LEARNED
  • Long Term Cardiovascular Safety Trials: FDA guidance clearly signaled that future clinical trials should engage sicker patients to assess whether they are at greater risk of cardiovascular events. This will likely require longer clinical trials. FDA guidance indicated 2-4 years. This lays down a critical market entry factor for future anti-diabetic therapies.
  • Risk Assessment & Post-Marketing Trials: When the Onglyza (saxagliptin) team finally met with the FDA in 2009, the Endocrinologic and Metabolic Drugs Advisory Committee articulated various “Voting Questions” that reflected the essence of FDA safety concerns. Moreover, these questions reflect the hurdles that future anti-diabetes therapies will need to address.

METHODOLOGY

The data for this case study was collected utilizing secondary research.

Industries Profiled:
Pharmaceutical


Companies Profiled:
AstraZeneca; Bristol-Myers Squibb


If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.